Testing a heart procedure for leak from the mitral valve
Part of Heart & circulation clinical trials.
This trial studies an “epicardial” device placed during planned heart surgery to reduce mitral valve leaking (“mitral regurgitation”). If you have moderate-to-severe valve leak from ischemic heart disease and are already scheduled for heart surgery, this may help improve how well the valve works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 22 or older
- You have moderate or worse mitral valve leak caused by ischemic (reduced blood flow) heart disease
- You are scheduled for heart surgery such as CABG (or are on a transplant waiting list)
- Before surgery, you should be on stable heart-failure medicines for up to 90 days (doses optimized as recommended)
- You must be able to have the needed heart ultrasound measurements before the procedure
- You must be able to use the consent form and understand the trial plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device for people whose mitral valve leaks badly (grade 3+ or 4+) and who are not candidates for surgery. The device aims to fix the leak through a less invasive approach, and the study checks if it's safe and works well in daily life.
This trial tests a new device designed to fix a leaky mitral valve in people with heart failure. It may help you breathe easier and feel less tired if your valve leak is severe and medicines have not been enough.
This trial studies a new transcatheter (through the heart without open surgery) mitral valve treatment for people with severe mitral valve leaking who are too high-risk for standard surgery. It may help reduce valve leakage and improve symptoms, but it’s an early “first-in-human” device study.
This study looks at how long a new mitral valve treatment/device can stay working in people with moderate-to-severe or severe mitral valve leak. It may help avoid or delay surgery for people considered higher risk for mitral valve repair.
This trial tests a new device called the Capstan system to fix a leaky mitral valve (mitral regurgitation) without open-heart surgery. It may help people whose valve leak is moderate to severe and still have symptoms despite medicines.
This trial tests a procedure called transcatheter edge-to-edge repair (TEER) for people with a specific type of heart valve leak (functional mitral regurgitation) that is causing heart failure symptoms. The procedure is less invasive than open-heart surgery and aims to improve symptoms and quality of life.
Hear when a new Ischemic Mitral Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.